Key result
Propranolol pretreatment completely prevented carbachol-induced ventricular tachycardia and fibrillation in transgenic LQT3 mice.
Why the study?
Does propranolol prevent carbachol-induced ventricular tachycardia and fibrillation in a transgenic mouse model of LQT3?
Does propranolol prevent carbachol-induced ventricular tachycardia and fibrillation in a transgenic mouse model of LQT3?
Answers are grounded in this paper and cite their sources.
Propranolol effectively prevents carbachol-induced VT/VF in a transgenic mouse model of LQT3, supporting the initiation of beta-blocker therapy in LQT3 patients.
BACKGROUND: The efficacy of beta-blockers for treatment of patients with long QT syndrome type 3 (LQT3) has been repeatedly questioned, and it has been suggested that they might be detrimental for this genetic subgroup of patients with long QT syndrome (LQTS). The disquieting consequence has been that cardiologists confronted with LQT3 patients often do not even attempt pharmacologic therapy and implant cardioverter-defibrillators as first-choice treatment. However, the most recent clinical data indicate high efficacy of beta-blocker therapy in LQT3 patients. OBJECTIVE: The purpose of this study was to test the antiarrhythmic efficacy of beta-blockers in an established experimental model for LQT3. METHODS: After phenotypic validation of 65 ∆KPQ-SCN5A knock-in transgenic (TG) mice compared to 32 wild-type (WT) mice, we tested the effect of the arrhythmogenic cholinergic muscarinic agonist carbachol in 19 WT and 39 TG anesthetized mice, with and without pretreatment with propranolol given intraperitoneally. RESULTS: At the same heart rates, TG mice had a markedly longer QT interval than WT mice. Whereas carbachol had minor arrhythmic effects in the WT mice, it produced ventricular tachycardia (VT) and ventricular fibrillation (VF) in 55% of 20 TG mice. By contrast, in none of 19 TG mice pretreated with propranolol did VT/VF occur after carbachol injection. CONCLUSION: These experimental data indicate that, contrary to previous reports, beta-blockade effectively prevents VT/VF in a validated LQT3 model. Together with the most recent clinical data, these findings indicate that there is no reason for not initiating protective therapy with beta-blockers in LQT3 patients.
No takes yet. Share an insight, caveat, or question.
Calvillo et al. (2013) studied Long QT syndrome type 3 (LQT3) (n=97). Propranolol vs. No pretreatment was evaluated on Ventricular tachycardia (VT) and ventricular fibrillation (VF) after carbachol injection. Propranolol pretreatment completely prevented carbachol-induced ventricular tachycardia and fibrillation in transgenic LQT3 mice.
Synapse has enriched 10 related papers. Consider them for comparative context: